Esther Artime

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 17

Top Topics

Systematic Review

Clinical Practice

Cross Sectional

Top Venues

Advances in therapy

Patient preference and adherence

Pharmacoepidemiology and drug safety

Diabetes therapy : research, treatment and education of diabetes and related disorders

This page only lists publications with an associated author ORCID identifier.

Publications

Manuel Botana, Miguel Camafort, Raquel Campuzano Ruiz, Ana Cebrián, Manuel Gargallo Fernández, Héctor David de Paz, Jennifer Redondo-Antón, Esther Artime, Silvia Díaz-Cerezo, Miriam Rubio-de Santos
Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain. Advances in therapy (2024)
Fernando Gomez-Peralta, Isabel Leiva Gea, Natalia Duque, Esther Artime, Miriam Rubio-de Santos
Impact of Continuous Glucose Monitoring and its Glucometrics in Clinical Practice in Spain and Future Perspectives: A Narrative Review. Advances in therapy 41 (9) (2024)
Manuel Botana, Miguel Camafort, Raquel Campuzano Ruiz, Ana Cebrián, Manuel Gargallo Fernández, Héctor David de Paz, Jennifer Redondo-Antón, Esther Artime, Silvia Díaz-Cerezo, Miriam Rubio-de Santos
Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain. Advances in therapy 41 (9) (2024)
Manuel Botana, Miguel Camafort, Raquel Campuzano Ruiz, Ana Cebrián, Manuel Gargallo Fernández, Héctor David de Paz, Jennifer Redondo-Antón, Esther Artime, Silvia Díaz-Cerezo, Miriam Rubio-de Santos
Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain. Advances in therapy 41 (9) (2024)
Manuel Botana, Miguel Camafort, Raquel Campuzano Ruiz, Ana Cebrián, Manuel Gargallo Fernández, Héctor David de Paz, Jennifer Redondo-Antón, Esther Artime, Silvia Díaz-Cerezo, Miriam Rubio-de Santos
Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain. Advances in therapy 41 (9) (2024)
Fernando Gomez-Peralta, Isabel Leiva Gea, Natalia Duque, Esther Artime, Miriam Rubio-de Santos
Impact of Continuous Glucose Monitoring and its Glucometrics in Clinical Practice in Spain and Future Perspectives: A Narrative Review. Advances in therapy 41 (9) (2024)
Virginia Bellido, Natalia Duque, Rachel S Newson, Esther Artime, Erik Spaepen, Miriam Rubio de Santos, Jennifer Redondo-Antón, Silvia Díaz-Cerezo, Jorge Navarro
The Burden of Suboptimal Insulin Dosing in People with Diabetes in Spain: Barriers and Solutions from the Physician Perspective. Patient preference and adherence 18 (2024)
Virginia Bellido, Natalia Duque, Rachel S Newson, Esther Artime, Erik Spaepen, Miriam Rubio de Santos, Jennifer Redondo-Antón, Silvia Díaz-Cerezo, Jorge Navarro
The Burden of Suboptimal Insulin Dosing in People with Diabetes in Spain: Barriers and Solutions from the Physician Perspective. Patient preference and adherence 18 (2024)
Fernando Gomez-Peralta, Isabel Leiva Gea, Natalia Duque, Esther Artime, Miriam Rubio-de Santos
Impact of Continuous Glucose Monitoring and its Glucometrics in Clinical Practice in Spain and Future Perspectives: A Narrative Review. Advances in therapy (2024)
Manuel Botana, Miguel Camafort, Raquel Campuzano Ruiz, Ana Cebrián, Manuel Gargallo Fernández, Héctor David de Paz, Jennifer Redondo-Antón, Esther Artime, Silvia Díaz-Cerezo, Miriam Rubio-de Santos
Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain. Advances in therapy 41 (9) (2024)
Fernando Gomez-Peralta, Isabel Leiva Gea, Natalia Duque, Esther Artime, Miriam Rubio-de Santos
Impact of Continuous Glucose Monitoring and its Glucometrics in Clinical Practice in Spain and Future Perspectives: A Narrative Review. Advances in therapy 41 (9) (2024)
Fernando Gomez-Peralta, Isabel Leiva Gea, Natalia Duque, Esther Artime, Miriam Rubio-de Santos
Impact of Continuous Glucose Monitoring and its Glucometrics in Clinical Practice in Spain and Future Perspectives: A Narrative Review. Advances in therapy 41 (9) (2024)
Francisco Javier Ampudia-Blasco, Natalia Duque, Esther Artime, Elena Caveda, Erik Spaepen, Silvia Díaz-Cerezo, Miriam Rubio- de Santos, Daniel Callejo Velasco, Mª Pilar Bahíllo-Curieses
Which people with diabetes are treated with a disposable, half-unit insulin pen? A real-world, retrospective, database study in Spain. Endocrinology, diabetes & metabolism (2023)
Miriam Rubio-de Santos, Esther Artime, Natalia Duque, Silvia Díaz-Cerezo, Erik Spaepen, Ágata Carreño, Alberto Fernández
Profile of Patients with Diabetes Treated with Insulin Lispro 200 U/ml: A Real-World Study from Spain. Diabetes therapy : research, treatment and education of diabetes and related disorders 13 (6) (2022)
Esther Artime, Randip Kahlon, Ignacio Méndez, Tzuyung Kou, Macarena Garrido-Estepa, Nawab Qizilbash
Linking process indicators and clinical/safety outcomes to assess the effectiveness of abatacept (ORENCIA) patient alert cards in patients with rheumatoid arthritis. Pharmacoepidemiology and drug safety 29 (6) (2020)
Esther Artime, Nawab Qizilbash, Rafael Herruzo, Macarena Garrido-Estepa
Risk Minimisation Evaluation with Process Indicators and Behavioural or Health Outcomes in Europe: Systematic Review. Pharmaceutical medicine 34 (6) (2020)
Esther Artime, Irene Shui, Ignacio Mendez, Stephanie Tcherny-Lessenot, Pierre D'Arbigny, Noelia Alfaro, Nawab Qizilbash
Pre/post effectiveness evaluation of updated additional risk minimisation measures for an orphan disease: Myozyme (alglucosidase alfa) Safety Information Packet. Pharmacoepidemiology and drug safety 29 (1) (2019)